CTLA4 and hepatocellular carcinoma: Regulatory approvals for immune checkpoint inhibitors in HCC have been granted regardless of PD-L1 or CTLA-4 IHC status, as clinical trials have not consistently demonstrated predictive value for these markers in this context.